<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736576</url>
  </required_header>
  <id_info>
    <org_study_id>A5481126</org_study_id>
    <nct_id>NCT04736576</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy</brief_title>
  <acronym>JBCRG-26</acronym>
  <official_title>Prospective, Multicenter, Observational Study to Evaluate Patient-reported Outcome and Physical Activity Using Smartphone-based Application and Wearable Device in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Breast Cancer Research Group (JBCRG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, multicenter, observational study to evaluate PRO and physical&#xD;
      activity using smartphone-based application and wearable device in Japanese patients with&#xD;
      HR+/HER2- advanced breast cancer (ABC). Patients will be enrolled into either palbociclib&#xD;
      plus endocrine therapy group (Group 1) or endocrine monotherapy group (Group 2) based on the&#xD;
      discretion of the treating physician under routine clinical practice. Total target number of&#xD;
      patients is approximately one-hundred in this study (About 50 patients in each group).&#xD;
      Enrolled patients will download a smartphone-based application for electronic PRO (ePRO), be&#xD;
      provided access to and trained on the use of the application to complete baseline, weekly,&#xD;
      and cycle based assessments for 6 cycles (24 weeks). In addition, enrolled patients will be&#xD;
      provided with wearable device and requested to wear the device at all-times, except of while&#xD;
      bathing and sleeping, for 6 cycles (24 weeks).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PRO as measured by EORTC-QLQ-C30 collected via smartphonebased application.</measure>
    <time_frame>Baseline to end of study (6 cycles of initiated treatment) or 24 weeks if patient discontinues initiated treatement before completion of 6 cycles.</time_frame>
    <description>EORTC-QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical activities as measured by wearable device.</measure>
    <time_frame>Baseline to end of study (6 cycles of initiated treatment) or 24 weeks if patient discontinues initiated treatement before completion of 6 cycles.</time_frame>
    <description>Physical activity metrics (eg, sedentary time) will be derived by Actigraph's algorithms based on the raw data collected by the device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EORTC-QLQ-C30 and physical activity versus patient-reported symptom as measured by Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) collected via smartphone-based application.</measure>
    <time_frame>Baseline to end of study (6 cycles of initiated treatment) or 24 weeks if patient discontinues initiated treatement before completion of 6 cycles.</time_frame>
    <description>PRO-CTCAE: seventy-eight symptom terms that are common in oncology clinical trials can be evaluable, and each of symptom terms is assessed relative to one or more distinct attributes, including frequency, severity, and/or interference with usual or daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient treatment satisfaction question</measure>
    <time_frame>Baseline to end of study (6 cycles of initiated treatment) or 24 weeks if patient discontinues initiated treatement before completion of 6 cycles.</time_frame>
    <description>Treatment satisfaction will be evaluated with single item question</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Palbociclib plus endocrine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Endocrine monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wearable device</intervention_name>
    <description>As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult women (â‰¥ 20 years of age)&#xD;
&#xD;
          2. Diagnosis of adenocarcinoma of the breast with evidence of metastatic disease or&#xD;
             advanced disease not amenable to resection or radiation therapy with curative intent.&#xD;
&#xD;
          3. Documented evidence of HR+/HER2- tumor based on the patient's surgical specimen or&#xD;
             most recent tumor biopsy.&#xD;
&#xD;
          4. Initiating first or second line treatment at study entry with one of the following&#xD;
             therapies:&#xD;
&#xD;
             palbociclib plus endocrine therapy or endocrine monotherapy&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status = 0~1.&#xD;
&#xD;
          6. Owns or has regular access to an Apple iPhone or Android phone.&#xD;
&#xD;
          7. Willing and able to complete collection of data via smartphone-based application.&#xD;
&#xD;
          8. Willing and able to wear the wearable device for approximately 6 months.&#xD;
&#xD;
          9. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the patient has been informed of all pertinent aspects of the study.&#xD;
&#xD;
         10. Able to read and understand Japanese&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient is participating in any interventional clinical trial that includes&#xD;
             investigational or marketed products. Patients participating in other&#xD;
             investigator-initiated research or non-interventional studies can be included as long&#xD;
             as their standard of care is not altered by the study.&#xD;
&#xD;
          2. The patient is on active treatment for other malignancies other than ABC.&#xD;
&#xD;
          3. The patient's life style is fluctuating in weekly-basis (eg, shift-time worker), which&#xD;
             may have high impact on physical activity assessment based to investigator's&#xD;
             discretion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroko Bando</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Breast, Thyroid and Endocrine Surgery, University of Tsukuba Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunagawa City Medical Center</name>
      <address>
        <city>Sunagawa</city>
        <state>Hokkaido</state>
        <zip>073-0196</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sakai City Medical Center</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>593-8304</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kita-adachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seirei Hamamatsu General Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>430-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Minato</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima Prefectural Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A5481126</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prospective</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Observational study</keyword>
  <keyword>Japan</keyword>
  <keyword>HR+/HER2- advanced breast cancer</keyword>
  <keyword>Palbociclib</keyword>
  <keyword>European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (items) (EORTC-QLQ-C30)</keyword>
  <keyword>Physical activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

